This week's contributor is Ian Chant, General Manager, Aker BioMarine Antarctic Australia.
THE recent launch of the Omega-3 Index Test in Australia brings a new innovative diagnostic tool to pharmacies, direct from krill oil supplier, Aker BioMarine. This simple finger-prick test, with results delivered within 14 days, is a marker of an individual's omega-3 status and is designed to measure levels of the omega-3 EPA and DHA fatty acids in red blood cells.
Healthy levels of these omega-3s not only support good brain function and help reduce joint inflammation in arthritis sufferers , but they also help lower blood triglyceride levels1, and, most importantly, support cardiovascular health by reducing the risk of sudden cardiac failure.2
The target Omega-3 Index is 8% or above, which is associated with the lowest risk for developing cardiovascular disease. An Omega-3 Index of 4% or less is linked with relatively high risk.
The introduction of the Omega-3 Index Test will allow pharmacists to better understand consumer risk and requirements around omega-3s and support evidence-based recommendations on increasing levels through diet and supplementation with krill oil, if necessary.
Aker BioMarine, the supplier of krill oil supplements for many pharmacy brands, is committed to empowering pharmacists and other healthcare professionals with tools and information about omega-3 EPA and DHA and their role in improving overall health.
For more information on omega-3s and how you can access the Omega-3 Index Test Kits, visit www.omega3.net.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 16
